• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

川崎病静脉注射大剂量免疫球蛋白后出现免疫性溶血、弥散性血管内凝血及血清病。

Immune hemolysis, disseminated intravascular coagulation, and serum sickness after large doses of immune globulin given intravenously for Kawasaki disease.

作者信息

Comenzo R L, Malachowski M E, Meissner H C, Fulton D R, Berkman E M

机构信息

Department of Medicine, New England Medical Center, Boston.

出版信息

J Pediatr. 1992 Jun;120(6):926-8. doi: 10.1016/s0022-3476(05)81964-x.

DOI:10.1016/s0022-3476(05)81964-x
PMID:1593353
Abstract

One week after treatment with intravenously administered immune globulin and aspirin, a child with Kawasaki disease had persistent fever and an increase in coronary artery diameter to greater than 3 mm. Two additional doses of immune globulin were given intravenously. Rapid hemolysis occurred, followed by disseminated intravascular coagulation and serum sickness. Clinicians should be aware that immune globulin preparations contain antibodies to blood-type antigens that may cause significant hemolysis and disseminated intravascular coagulation.

摘要

在接受静脉注射免疫球蛋白和阿司匹林治疗一周后,一名川崎病患儿仍持续发热,冠状动脉直径增加至大于3毫米。又静脉注射了两剂免疫球蛋白。随后迅速发生溶血,继之出现弥散性血管内凝血和血清病。临床医生应意识到免疫球蛋白制剂含有针对血型抗原的抗体,可能会导致严重溶血和弥散性血管内凝血。

相似文献

1
Immune hemolysis, disseminated intravascular coagulation, and serum sickness after large doses of immune globulin given intravenously for Kawasaki disease.川崎病静脉注射大剂量免疫球蛋白后出现免疫性溶血、弥散性血管内凝血及血清病。
J Pediatr. 1992 Jun;120(6):926-8. doi: 10.1016/s0022-3476(05)81964-x.
2
Extremely refractory Kawasaki disease with disseminated intravascular coagulation.伴有弥散性血管内凝血的极重度难治性川崎病
Cardiol Young. 2017 Jul;27(5):1004-1007. doi: 10.1017/S1047951116002742. Epub 2017 Mar 7.
3
Economic evaluation of intravenous immune globulin therapy for Kawasaki syndrome.川崎病静脉注射免疫球蛋白治疗的经济学评价
J Pediatr. 1993 Apr;122(4):538-42. doi: 10.1016/s0022-3476(05)83532-2.
4
[Kawasaki disease--two case reports].[川崎病——两例病例报告]
Pol Merkur Lekarski. 1997 Jul;3(13):20-1.
5
Kawasaki disease presenting with disseminated intravascular coagulation: report of one case.
Zhonghua Min Guo Xiao Er Ke Yi Xue Hui Za Zhi. 1994 Jul-Aug;35(4):341-4.
6
Intravenous gamma-globulin treatment in Kawasaki disease.川崎病的静脉注射丙种球蛋白治疗
Acta Paediatr Jpn. 1991 Dec;33(6):805-10. doi: 10.1111/j.1442-200x.1991.tb02612.x.
7
Comparative safety and efficacy of two immune globulin products in Kawasaki disease.两种免疫球蛋白产品在川崎病中的安全性和疗效比较
J Pediatr. 1995 Jun;126(6):1000-3. doi: 10.1016/s0022-3476(95)70233-4.
8
Possible mechanisms for intravenous immunoglobulin-associated hemolysis: clues obtained from review of clinical case reports.静脉注射免疫球蛋白相关溶血的可能机制:从临床病例报告回顾中获得的线索
Transfusion. 2015 Jul;55 Suppl 2:S59-64. doi: 10.1111/trf.13090.
9
Infliximab for intensification of primary therapy for Kawasaki disease: a phase 3 randomised, double-blind, placebo-controlled trial.英夫利昔单抗强化川崎病一线治疗:一项 3 期随机、双盲、安慰剂对照试验。
Lancet. 2014 May 17;383(9930):1731-8. doi: 10.1016/S0140-6736(13)62298-9. Epub 2014 Feb 24.
10
Hemolytic adverse events with immune globulin products: product factors and patient risks.免疫球蛋白产品相关的溶血性不良事件:产品因素与患者风险
Transfusion. 2015 Jul;55 Suppl 2:S2-5. doi: 10.1111/trf.13148.

引用本文的文献

1
Shaanxi Provincial Diagnosis and Treatment Center of Kawasaki Disease.陕西省川崎病诊疗中心。
Zhongguo Dang Dai Er Ke Za Zhi. 2021;23(9):867-876. doi: 10.7499/j.issn.1008-8830.2107110.
2
Hemolysis From Intravenous Immunoglobulin in Obese Patients With Kawasaki Disease.静脉注射免疫球蛋白导致川崎病肥胖患者溶血
Front Pediatr. 2020 Apr 3;8:146. doi: 10.3389/fped.2020.00146. eCollection 2020.
3
Laboratory Markers in Incomplete Kawasaki Disease according to Coronary Artery Outcome.根据冠状动脉转归情况分析不完全川崎病的实验室指标
Korean Circ J. 2018 Apr;48(4):287-295. doi: 10.4070/kcj.2017.0342.
4
On the dark side of therapies with immunoglobulin concentrates: the adverse events.免疫球蛋白浓缩物治疗的阴暗面:不良事件。
Front Immunol. 2015 Feb 5;6:11. doi: 10.3389/fimmu.2015.00011. eCollection 2015.
5
Hemolytic anemia following intravenous immunoglobulin therapy in patients treated for Kawasaki disease: a report of 4 cases.川崎病治疗后静脉注射免疫球蛋白治疗引起的溶血性贫血:4 例报告。
Pediatr Rheumatol Online J. 2012 Apr 16;10(1):10. doi: 10.1186/1546-0096-10-10.
6
RhIG for the treatment of immune thrombocytopenia: consensus and controversy (CME).人免疫球蛋白治疗免疫性血小板减少症:共识与争议(CME)。
Transfusion. 2012 May;52(5):1126-36; quiz 1125. doi: 10.1111/j.1537-2995.2011.03384.x. Epub 2011 Oct 7.
7
Acute hemolysis after high-dose intravenous immunoglobulin therapy in highly HLA sensitized patients.高剂量静脉注射免疫球蛋白治疗高度 HLA 致敏患者后的急性溶血。
Clin J Am Soc Nephrol. 2009 Dec;4(12):1993-7. doi: 10.2215/CJN.04540709. Epub 2009 Oct 15.
8
Kawasaki disease with DIC as a complication.川崎病并发弥散性血管内凝血。
Indian J Pediatr. 2007 Nov;74(11):1049. doi: 10.1007/s12098-007-0197-5.
9
Intravenous immunoglobulin treatment in vasculitis and connective tissue disorders.静脉注射免疫球蛋白在血管炎和结缔组织疾病中的治疗应用。
J Neurol. 2006 Sep;253 Suppl 5:V39-49. doi: 10.1007/s00415-006-5006-y.
10
Intravenous immunoglobulin therapy in vasculitis: speculation or evidence?静脉注射免疫球蛋白疗法治疗血管炎:猜测还是证据?
Clin Rev Allergy Immunol. 2005 Dec;29(3):237-45. doi: 10.1385/CRIAI:29:3:237.